Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis.

Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ.

Clin Infect Dis. 2013 Jan;56(2):272-82. doi: 10.1093/cid/cis857. Epub 2012 Oct 16. Review.

PMID:
23074314
2.

The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.

Yost RJ, Cappelletty DM; RECEIPT Study group..

Pharmacotherapy. 2011 Aug;31(8):767-75. doi: 10.1592/phco.31.8.767.

PMID:
21923603
3.

Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review.

Mah GT, Mabasa VH, Chow I, Ensom MH.

Ann Pharmacother. 2012 Feb;46(2):265-75. doi: 10.1345/aph.1Q378. Epub 2012 Jan 24. Review.

PMID:
22274145
4.

Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis.

Yang H, Zhang C, Zhou Q, Wang Y, Chen L.

PLoS One. 2015 Jan 9;10(1):e0116769. doi: 10.1371/journal.pone.0116769. eCollection 2015. Review.

5.

Is extended or continuous infusion of carbapenems the obvious solution to improve clinical outcomes and reduce mortality?

Frippiat F, Vercheval C, Lambermont B, Damas P.

Clin Infect Dis. 2013 Jul;57(2):324-5. doi: 10.1093/cid/cit205. Epub 2013 Apr 1. No abstract available.

PMID:
23547169
6.

Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?

Attivi D, Gibaud S.

Ann Pharm Fr. 2014 May;72(3):146-51. doi: 10.1016/j.pharma.2013.12.006. Epub 2014 Jan 20. Review.

PMID:
24780830
7.

Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review.

Yusuf E, Spapen H, Piérard D.

J Crit Care. 2014 Dec;29(6):1089-95. doi: 10.1016/j.jcrc.2014.07.033. Epub 2014 Aug 7. Review.

PMID:
25179412
8.

Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.

Lodise TP Jr, Lomaestro B, Drusano GL.

Clin Infect Dis. 2007 Feb 1;44(3):357-63. Epub 2007 Jan 2.

PMID:
17205441
9.

Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.

Cotrina-Luque J, Gil-Navarro MV, Acosta-García H, Alfaro-Lara ER, Luque-Márquez R, Beltrán-García M, Bautista-Paloma FJ.

Int J Clin Pharm. 2016 Feb;38(1):70-9.

PMID:
26474861
11.

Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.

Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R.

Pharmacotherapy. 2002 Apr;22(4):471-83.

PMID:
11939682
12.

Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.

Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD.

Int J Antimicrob Agents. 2005 Jan;25(1):62-7.

PMID:
15620828
13.

Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.

Winstead EM, Ratliff PD, Hickson RP, Mueller JE, Judd WR.

Int J Clin Pharm. 2016 Oct;38(5):1087-93. doi: 10.1007/s11096-016-0334-1. Epub 2016 Jun 22.

PMID:
27333796
14.

Pharmacokinetic evaluation of piperacillin-tazobactam.

Hayashi Y, Roberts JA, Paterson DL, Lipman J.

Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):1017-31. doi: 10.1517/17425255.2010.506187. Review.

PMID:
20636224
15.

Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.

Réa-Neto A, Niederman M, Lobo SM, Schroeder E, Lee M, Kaniga K, Ketter N, Prokocimer P, Friedland I.

Curr Med Res Opin. 2008 Jul;24(7):2113-26. doi: 10.1185/03007990802179255 . Epub 2008 Jun 11.

PMID:
18549664
16.

Comparison of acute renal injury associated with intermittent and extended infusion piperacillin/tazobactam.

McCormick H, Tomaka N, Baggett S, Heierman T, LaFosse J, Gilbert S, Imhof K.

Am J Health Syst Pharm. 2015 Jun 1;72(11 Suppl 1):S25-30. doi: 10.2146/sp150007.

PMID:
25991590
17.

Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients.

Lee GC, Liou H, Yee R, Quan CF, Neldner K.

Clin Ther. 2012 Dec;34(12):2297-300. doi: 10.1016/j.clinthera.2012.11.005. Epub 2012 Nov 27.

PMID:
23195962
18.

Rationale and evidence for extended infusion of piperacillin-tazobactam.

Kaufman SE, Donnell RW, Hickey WS.

Am J Health Syst Pharm. 2011 Aug 15;68(16):1521-6. doi: 10.2146/ajhp100694. Review.

PMID:
21817083
19.

Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections.

Patel GW, Patel N, Lat A, Trombley K, Enbawe S, Manor K, Smith R, Lodise TP Jr.

Diagn Microbiol Infect Dis. 2009 Jun;64(2):236-40. doi: 10.1016/j.diagmicrobio.2009.03.002.

PMID:
19500529
20.

Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.

Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP.

J Antimicrob Chemother. 2005 Aug;56(2):388-95. Epub 2005 Jul 7.

PMID:
16002420

Supplemental Content

Support Center